Automated lamellar therapeutic keratoplasty (ALTK) and Descemet stripping automated endothelial keratoplasty (DSAEK) are both safe and effective techniques for corneal transplantation.
Automated lamellar therapeutic keratoplasty (ALTK) and Descemet stripping automated endothelial keratoplasty (DSAEK) are both safe and effective techniques for corneal transplantation, according to Paolo Garimoldi and colleagues from Ospedale di Circolo, Italy.
Twenty eyes, 18 affected by keratocone and 2 by stromal opacity for herpes simplex keratitis, underwent ALTK. In eyes with keratocone, releasing penetrating stromal incisions were performed and a thicker graft obtained from a donor cornea, which was transplanted. The 18 eyes affected by Fuchs endothelial dystrophy underwent DSAEK; after removing the endothelium and Descemet membrane, a graft of deep stroma and endothelium from the donor cornea was inserted in the anterior chamber and positioned with an air-bubble.
Eyes treated with ALTK demonstrated very good graft transparency and an excellent quality of interface. No rejection reactions were noted and early temporary de-epithelialization occurred in 20% of cases. Best corrected visual acuity (BCVA) was 0.6 or better in 90% of subjects after three months follow-up. The eyes treated with DSAEK demonstrated a progressive increase of corneal transparency and the BCVA was 0.5 or better in 70% of cases after three months follow-up.
It was concluded that both procedures are safe and effective, particularly with regards the fast visual recovery and low level of complications.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.